Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

PURPOSE: The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kader, Yasser Abdel, Le Chevalier, Thierry, El-Nahas, Tamer, Sakr, Amr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702548/
https://www.ncbi.nlm.nih.gov/pubmed/23836994
http://dx.doi.org/10.2147/OTT.S45906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702548/
https://www.ncbi.nlm.nih.gov/pubmed/23836994
http://dx.doi.org/10.2147/OTT.S45906

Ejemplares similares